Century Therapeutics EBIT Margin

What does Century Therapeutics do? Century Therapeutics develops off-the-shelf cell therapies for cancer treatment, focusing on allogeneic approaches using induced pluripotent stem cells (iPSCs). The company's platform enables the creation of immune effector cells from iPSCs, incorporating CRISPR technology for gene editing. Product candidates include CNTY-101 targeting CD19 for B-cell lymphoma, CNTY-102 targeting CD19 and CD22 for relapsed B-cell malignancies, CNTY-107 for Nectin-4-expressing solid tumors, and CNTY-104 as a multi-specific collaboration program for acute myeloid leukemia. The firm aims to address unmet medical needs in solid tumors and hematological malignancies. Century Therapeutics generates revenue through the development and commercialization of its cell therapy products. The company's pipeline targets high-need cancer indications, with CNTY-101 and CNTY-102 focused on blood cancers and CNTY-107 targeting solid tumors. CNTY-104 is developed through a collaboration, indicating potential revenue from partnership agreements. The firm's technology platform supports multiple product candidates, allowing for diversified revenue streams from different therapeutic areas. The primary customers for Century Therapeutics' products are healthcare providers treating cancer patients, particularly in hematology and oncology departments. The company targets unmet medical needs in relapsed, refractory B-cell lymphoma, solid tumors, and acute myeloid leukemia. Its focus on allogeneic therapies positions it to serve patients requiring off-the-shelf treatments rather than personalized cell therapies. The company's product portfolio addresses specific molecular targets like CD19, CD22, and Nectin-4, aligning with current treatment paradigms in oncology. Century Therapeutics is one of the most popular companies on Eulerpool.